Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.

Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study. - A pilot study of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029601

Enrollment

Registered

2017-10-18

Start date

2017-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

pembrolizumab 200mg every 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)ECOG PS 2 or 3 2)Non-small cell lung cancer 3)Stage IIIB or IV or recurrence 4)PD-L1 tumor proportion score of 50% or greater 5)No sensitizing EGFR mutations or ALK translocations 6)Chemotherapy naive 7)Provided written informed consent 8)With adequate organ function

Exclusion criteria

Exclusion criteria: 1)Pleural effusion, ascites or pericardial effusion requiring drainage 2)Other cancers 3)Symptomatic brain metastasis and meningitis 4)With severe complication 5)Interstitial pneumonia on CT 6)Severe drug allergy 7)Active autoimmune disease that has required systemic treatment 8)Dementia 9)Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	—

Secondary

Measure	Time frame
Objective Response Rate Disease Control Rate Overall survival QOL	—

Countries

Japan

Contacts

Public ContactTakeshi Masuda

Hiroshima University Department of Respiratory Internal medicine, Hiroshima Univestity Hospital

ta-masuda@hiroshima-u.ac.jp082-257-5196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026